









918Acquired cold urticaria: Clinical features,
particular phenotypes, and disease
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Barcelona, Spain; and Lisbon, PortugalBackground: Data about special phenotypes, natural course, and prognostic variables of patients with
acquired cold urticaria (ACU) are scarce.Objectives: We sought to describe the clinical features and disease course of patients with ACU, with
special attention paid to particular phenotypes, and to examine possible parameters that could predict the
evolution of the disease.Methods: This study was a retrospective chart review of 74 patients with ACU who visited a tertiary referral
center of urticaria between 2005 and 2015.Results: Fourteen patients (18.9%) presented with life-threatening reactions after cold exposure, and 21
(28.4%) showed negative results after cold stimulation tests (classified as atypical ACU). Nineteen patients
(25.7%) achieved complete symptoms resolution at the end of the surveillance period and had no
subsequent recurrences. Higher rates of atypical ACU along with a lower likelihood of achieving complete
symptom resolution was observed in patients who had an onset of symptoms during childhood (P\ .05).
In patients with atypical ACU, shorter disease duration and lower doses of antihistamines required for
achieving disease control were detected (P \ .05). Age at disease onset, symptom severity, and cold
urticaria threshold values were found to be related to disease evolution (P\ .05).Limitations: This study was limited by its retrospective nature.Conclusions: The knowledge of the clinical predictors of the disease evolution along with the clinical
features of ACU phenotypes would allow for the establishment of an early and proper therapeutic strategy.
( J Am Acad Dermatol 2016;75:918-24.)
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cquired cold urticaria (ACU) represents a
form of inducible urticaria that is character-
ized by the development of wheals, angioe-
dema, or both in response to exposure to cold air,
solids, or liquids.1 ACU symptoms are usually limited
to areas of the skin that have been exposed to cold.ents of Dermatology, Hospital del Mar- Institut
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Deza et al 919However, extensive cold contact may result in
generalized symptoms, such as headache, dyspnea,
hypotension, and a loss of consciousness.1-3
A diagnosis of ACU is typicallymade in patientswith
a clinical history of wheals or angioedema after cold
exposure; the diagnosis should then be appropriately
verified with cold stimulation tests (CSTs), the iceCAPSULE SUMMARY
d Acquired cold urticaria is characterized
by the development of wheals,
angioedema, or both after cold
exposure.
d Age at diagnosis, disease severity, and
response to the ice cube challenge test
predicted both prognosis and response
to therapy.
d Proper characterization of the type of
acquired cold urticaria allows for
appropriate counseling and choice of
therapy.cube test being the traditional
standardized method.1,2,4 In
addition, objective methods,




used for the evaluation of the
critical temperature threshold
(CTT) and the cold stimulation
time threshold (CsTT)dare
helpful for assessing ACU
severity and monitoring ther-
apyefficacy.5-7 There is a small
percentage of patients that are
classified as having atypical
ACU; they have identical clin-
ical manifestations but these
cannotbe reproducedby stan-
dard CSTs. Therefore, the diagnosis of atypical ACU
relies largely on the patient’s clinical history.1,8
Although previous studies have shown the pri-
mary clinical features of ACU,9 data about particular
phenotypes and prognostic variables of the disease
in a large series of patients are currently scarce. The
aim of this study was to review the clinical, diag-
nostic, and therapeutic features along with the evo-
lution of different ACU phenotypes and to examine




This retrospective study was based on the review
of clinical charts from patients with primary (idio-
pathic) ACUwhowere referred to the Urticaria Clinic
of the Department of Dermatology of Hospital del
Mar (Barcelona) between January 2005 and
December 2015. The diagnosis of cold urticaria was
based on a patient’s clinical history of wheals,
angioedema, or both immediately after cold
exposure. Patients with positive evidence of an
underlying condition associated with the
induction of cold urticaria rash (also known as
‘‘secondary’’ ACU [eg, cryoglobulinemia, cold
agglutinins, cryofibrinogenemia, leukocytoclastic
vasculitis, drugs, or infectious diseases]) or familiar
forms of cold urticaria were excluded from the study.The local clinical research ethics committee from the
Hospital del Mar granted ethical approval for the
study.
Data collected
Following a systematized prospective clinical pro-
tocol, data about epidemiologic and clinical features,
diagnostic procedures, thera-
peutic outcomes, and disease
course were recorded from
each patient through chart
review.
Atopy was defined by
the presence of $1 of
the following manifestations:
atopic dermatitis, allergic
rhinitis, or allergic asthma.
Disease severity was catego-
rized into 3 types based on
the classification suggested
by Wanderer et al10: type I,
localized urticaria or angioe-
dema; type II, generalized
urticaria or angioedema
without hypotensive or res-
piratory symptoms; and typeIII, severe systemic reactions with $1 episodes
suggestive of hypotension (ie, dizziness, sensation
of fainting, disorientation, or shock) or respiratory
distress (eg, shortness of breath or wheezing). Cold
exposures that triggered symptoms were consid-
ered: water, solids, air (including the exposure to
cold environmental conditions), and eating frozen/
cold foods.
The diagnosis of ACU was supported by the ice
cube challenge test. As currently recommended, our
standard protocol consisted of the application of the
cold stimulus over the patient’s forearm for 5minutes
followed by 10 minutes of rewarming.4 The test was
considered positive if a coalescent wheal was elicited
over the application site. In addition, all patients
underwent threshold assessment using TempTest 3.0
at the baseline evaluation. The CsTT and the CTT
were defined as the shortest time and the highest
temperature, respectively, at which a wheal
appears through cold provocation.5 At the time of
testing, all patients were symptom-free and none had
received antihistamines or oral corticosteroids
during the 10 days before testing. Subjects without
wheal formation after the CSTs (ie, the ice cube test
and the TempTest) were diagnosed with atypical
ACU.
Treatment was based on the continuous intake of
second-generation H1-antihistamines at standard
dose. If patients did not perceive symptom
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were gradually increased up to 4 times the licensed
dose until a complete control of symptoms was
achieved. In refractory cases, alternative treatments
were considered. Disease control with a particular
treatment was defined as an improvement of the
signs and symptoms referred by the patient until they
did not cause interferences in daily life (therapeutic
objective). Antihistamine dosage was defined as the
maximum daily dose of medication required for
achieving disease control.
The assessment of ACU evolution at the end of the
surveillance period was based on the feeling of the
patient or the patient’s guardian, and accordingly
classified as follows: ‘‘resolution,’’ when complete
freedom of symptoms was achieved after normally
cold exposure in $1 winter season without medica-
tion; ‘‘improvement,’’ if decreased severity or fre-
quency of symptomswere notedwithout achieving a
complete resolution and still in need of treatment;
and ‘‘no improvement,’’ when the severity and
frequency of symptoms remained stable or increased
in spite of the correct treatment. Disease durationwas
defined as the time from symptom onset to the last
follow-up visit or until complete symptom resolu-
tion. In patients who achieved complete symptom
resolution, telephone interviews were performed to
know if there were disease recurrences.
Statistical analysis
Descriptive statistics were performed for each
variable. Variables were compared descriptively be-
tween the different subgroups of patients with ACU
using frequencies and percentages for categorical
variables and means and standard deviations for
quantitative variables. Categorical variables were
compared between groups using chi-squared and
Fischer’s exact tests, while qualitative variables were
compared using the ManneWhitney U and
KruskaleWallis H tests. All calculated P values # .05
were considered statistically significant.
RESULTS
Description of the study population
During the study period, 1030 patients with
chronic urticaria were referred to our department.
Seventy-four patients (7.2%) presented with definite
symptoms of ACU andwere included in the study. All
these patients were diagnosed with idiopathic ACU
because no secondary causes were found. The
clinical characteristics of the study population are
summarized in Table I. Forty-seven patients (63.5%)
were female; the mean age was 38.3 6 19.0 years,
while the mean age at symptoms onset was
32.0 6 18.8 years. The mean diagnostic delay was24.5 months (range, 1-144 months). Twenty-five
patients (33.8%) had a personal history of atopy.
Twenty-five patients (33.8%) presented with a
localized form of ACU (type I), and 49 patients
(66.2%) experienced generalized urticaria. The most
frequent cold stimulus that induced symptoms was
cold water, which was a trigger in 54 patients
(73.0%), followed by exposure to cold air (58.1%).
Twenty-one patients (28.4%) had a negative result
after the ice cube provocation test. In these patients,
nowheal formationwas detectedwith the TempTest;
therefore, CTT and CsTTwere not measurable. In the
remaining 53 patients with a positive ice cube test,
the mean CTT was 14.0 6 7.28C and the mean CsTT
was 2.9 6 1.4 minutes.
Regarding the therapeutic outcomes, 73 patients
(98.6%) were treated with different types of H1-
antihistamines, achieving disease control in 62 pa-
tients (84.9%). Fifty-two of these 62 patients (83.9%)
achieved disease control with 1 or 2 daily doses of
antihistamines (21 and 31 subjects, respectively). The
remaining 10 patients (16.1%) required higher doses.
Cyclosporine and omalizumab were prescribed in 3
patients each; clinical improvement was shown in
only 1 patient treated with cyclosporine, while all 3
patients (100%) who were treated with omalizumab
achieved disease control.
The mean duration of surveillance was
7.56 3.8 years. In 46 patients (62.2%), disease evolu-
tion at the end of the surveillance periodwas classified
as ‘‘improvement,’’ whereas 9patients (12.2%) showed
‘‘no improvement.’’ The remaining 19 patients (25.7%)
showed complete symptom resolution, with a mean
disease duration until resolution of 5.1 years (range,
1-24 years). No disease recurrences were recorded in
these patients. According to the KaplaneMeier anal-
ysis, it was estimated that the percentage of patients
showing complete symptom resolution was 26.6%
during the first 5 years of the disease and 44.5% during
thefirst 10 years (Supplementary Fig 1; available online
at www.jaad.org).
Disease severity
Severity of symptoms was found to be statistically
significant related to the rate of disease control by
using antihistamines (P = .002), the antihistamine
dosage required (P \ .001), disease duration
(P = .03), and evolution (P = .03; Table II). In
addition, the unique exposure significantly related
to symptom severity was cold water (P = .01).
Pediatric and adult-onset acquired cold
urticaria
Twenty patients (27.0%) with an early onset of
symptoms (#18years of age)were classified ashaving





ACU (n = 20)
Adult-onset
ACU (n = 54) P value
Atypical
ACU (n = 21)
Positive
CST (n = 53) P value
Sex, n (%)
Female 47 (63.5) 13 (65.0) 34 (63.0) .87 12 (57.1) 35 (66.0) .47
Male 27 (36.5) 7 (35.0) 20 (37.0) 9 (42.9) 18 (34.0)
Mean age at symptom onset, y
(range)
32.0 (1-89) 9.1 (1-18) 40.5 (19-89) NA 28.7 (1-89) 33.4 (1-65) .22
Atopy, n (%) 25 (33.8) 7 (35.0) 18 (33.3) .89 5 (23.8) 20 (37.7) .25
Disease severity, n (%)
I 25 (33.8) 6 (30.0) 19 (35.2) .70 9 (42.9) 16 (30.2) .14
II 35 (47.3) 9 (45.0) 26 (48.1) 11 (52.4) 24 (45.3)
III 14 (18.9) 5 (25.0) 9 (16.7) 1 (4.8) 13 (24.5)
Cold trigger, n (%)
Water 54 (73.0) 15 (75.0) 39 (72.2) .81 14 (66.7) 40 (75.5) .44
Solids 28 (37.8) 6 (30.0) 22 (40.7) .39 6 (28.6) 22 (41.5) .30
Air 43 (58.1) 14 (70.0) 29 (53.7) .20 15 (71.4) 28 (52.8) .14
Food 5 (6.8) 0 (0) 5 (9.3) .31 0 (0) 5 (9.4) .31
Ice cube test, n (%)
Positive 53 (71.6) 10 (50.0) 43 (79.6) .01* NA NA NA
Negative 21 (28.4) 10 (50.0) 11 (20.4)
Mean CsTT, min (range) 2.9 (1-5) 3.0 (1-5) 2.9 (1-5) .99 NA 3.0 (1-5) NA
Mean CTT, 8C (range) 14.0 (4-26) 11.6 (4-26) 14.6 (4-26) .21 NA 14.0 (4-26) NA
Disease control with anti-H1, n (%) 62 (83.8) 17 (85.0) 45 (83.3) .86 19 (90.5) 43 (81.1) .33
Mean anti-H1 daily dosage, (range)
y 2.1 (1-4) 2.0 (1-4) 2.2 (1-4) .63 1.4 (1-2) 2.4 (1-4) .001*
Disease evolution, n (%)
Resolution 19 (25.7) 1 (5.0) 18 (33.3) .03* 4 (19.0) 15 (28.3) .31
Improvement 46 (62.2) 16 (80.0) 30 (55.6) 16 (76.2) 30 (56.6)
No improvement 9 (12.2) 3 (15.0) 6 (11.1) 1 (4.8) 8 (15.1)
Mean disease duration, y (range) 5.3 (1-25) 6.9 (1-16) 4.8 (1-25) .43 4.3 (1-11) 5.8 (1-25) .02*
ACU, Acquired cold urticaria; CST, cold stimulation test; anti-H1, histamine H1-receptor antagonist; CsTT, cold stimulation time threshold; CTT,
critical temperature threshold; NA, not applicable.
*Statistically significant.
yThe standard antiH1 dose = 1.
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was higher in this population than in patients with
adult-onset ACU (50.0% vs 20.4%, respectively;
P = .01). No statistically significant differences were
found between these 2 groups regarding disease
severity, cold urticaria triggers, or rate of disease
control using antihistamines. However, different dis-
ease evolutions were found, with a lower rate of
symptom resolution in the patients with pediatric-
onset ACU (5% vs 33.3%; P = .03).
Results of the cold stimulation tests
Twenty-one patients (28.4%) were classified as
having atypical ACU based on the negative CSTs
results. Some variables, such as symptom severity,
cold urticaria triggers, and disease evolution were
found to be similar between patients with atypical
and typical ACU. Although the frequency of patients
achieving disease control using antihistamines was
also similar in both groups (90.5% vs 81.1%, respec-
tively), the antihistamine dosage required was lower
in patients with atypical ACU (the mean daily dose ofmedication was 1.4 times the licensed dose vs 2.4
times the licensed dose; P = .001). Moreover, disease
duration was shorter in patients with atypical ACU
compared with patients with positive CSTs (4.3 vs
5.8 years; P = .02).
Threshold assessment
CTT and CsTT values measured at the baseline
evaluation were found to be statistically significant
related to disease severity (P = .004 and P = .009,
respectively; Fig 1). CTT was also related to disease
evolution (P= .03). CsTTvalueswere slightly higher in
patients with complete symptom resolution at the end
of the surveillanceperiod than the ‘‘improvement’’ and
‘‘no improvement’’ groups; however, this trend was
not statistically significant (P = .54; Supplementary
Fig 2; available online at www.jaad.org).
DISCUSSION
Cold urticaria is a cutaneous disorder that repre-
sents a small proportion of chronic urticarias (7-8% in
our series). ACU can affect subjects from both sexes
Fig 1. A, Critical temperature threshold (CTT) and (B) cold stimulation time threshold (CsTT)
values by categories of disease severity (P = .004 and P = .009, respectively).
Table II. Disease severity of patients with acquired cold urticaria
Variables
ACU type
P valueI (n = 25) II (n = 35) III (n = 14)
Mean age at symptom onset, y (range) 34.9 (2-89) 31.1 (1-61) 29.3 (1-65) .74
Atopy, n (%) 6 (24.0) 13 (37.1) 6 (42.9) .42
Cold trigger, n (%)
Water 13 (52.0) 28 (80.0) 13 (92.9) .01*
Solids 10 (40.0) 14 (40.0) 4 (28.6) .73
Air 16 (64.0) 22 (62.9) 5 (35.7) .17
Food 2 (8.0) 2 (5.7) 1 (7.1) .74
Disease control with anti-H1, n (%) 25 (100) 30 (85.7) 8 (57.1) .002*
Mean anti-H1 daily dosage,
y (range) 1.4 (1-2) 2.1 (1-4) 3.1 (2-4) \.001*
Disease evolution, n (%)
Resolution 9 (36.0) 9 (25.7) 1 (7.1) .03*
Improvement 16 (64.0) 21 (60.0) 9 (64.3)
No improvement 0 (0) 5 (14.3) 4 (28.6)
Mean disease duration, y (range) 4.2 (1-24) 5.6 (1-22) 6.6 (2-25) .03*
ACU, Acquired cold urticaria; anti-H1, histamine H1-receptor antagonist.
*Statistically significant.
yThe standard antiH1 dose = 1.
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postulated that middle-aged women are most often
affected.2,5 Similarly, we found a female predomi-
nance in our population, and the most frequent age
at disease onset ranged from 23 to 41 years.
In the present study, disease severity was classi-
fied based on the extension of the urticarial reaction
and the presence of hypotensive or respiratory
symptoms. Accordingly, almost 19% of patients
with ACU can present with life-threatening reactions.
The only exposure that was found to be related to
disease severity was cold water; 93% of the patients
who suffered systemic reactions were exposed to
this stimulus. This can be explained because aquatic
activities usually include a wide skin area exposure
and involve longer periods of time. Therefore, itseems appropriate for patients with ACU to avoid or
minimize the use of aquatic activities. Our results
also suggest a relationship between symptom
severity and both the disease prognosis and the
therapeutic response. Thus, in patients with severe
ACU, a longer duration of disease, lower rates of
complete symptom resolution, and a poorer thera-
peutic response to antihistamines would be ex-
pected. Therefore, a precise definition of disease
severity at the baseline evaluation is recommended,
and when severe forms of ACU are detected, a closer
follow-up and an early treatment with higher doses
of antihistamines seem advisable.
Different phenotypes of patients with ACU were
identified. Although clinical features of cold urticaria
seem to be similar regardless of the age at symptom
J AM ACAD DERMATOL
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showed some differences; ACU was more difficultly
induced through the ice cube test or the TempTest,
and a complete resolution of symptomswas less likely
to be achieved. These results are consistent with a
previous pediatric study3 inwhich complete symptom
resolutionwas achieved inonly 2of 30 (7.4%) children
with cold urticaria, and 41% of the patients had
negative CSTs. Similarly, Santaolalla et al11 noted a
full recovery of symptoms in only 1 of 12 pediatric
patients analyzed. Therefore, patients with ACU who
have an early onset of symptoms and their families
should receive counseling regarding the particular
prognosis of the disease. Because a longer duration of
disease might be expected, these patients should
understand their condition and integrate it into their
daily lives. Future long-term studies are necessary to
validate these data and to fully understand the natural
history of ACU in children.
Twenty-eight percent of our patients had negative
CSTs and were diagnosed with atypical ACU. The
frequency of atypical ACU in previous series varied
between 8% and 49%.3,9,10,12 Although the knowledge
of this entity, especially regarding its natural history, is
currently scarce, it has been postulated that these
patients would need total body cooling to reflect cold
urticaria symptoms.1 A previous report also suggested
a higher incidence of systemic reactions in these
patients (10patientswith atypical ACUwere analyzed,
6 presented with type II reactions and 2 with type III
reactions).10 However, in our study, no statistically
significant relationship was found between patients
with atypical ACU and symptom severity (21 atypical
cases; 11 type II and 1 type III). Nevertheless, a shorter
duration of disease and lower doses of antihistamines
required for achieving disease control were found in
patients with atypical ACU. In addition, it seems that
atypical cases have a shorter duration of cold urticaria
symptoms regardless of the ageof diseaseonset (eg, in
our series, ‘‘classic’’ [ice cube positive] ACU in children
lasted longer [7.6years] compared toadults [5.2 years]).
Therefore, clinicians should be aware that there is a
subgroup of patients who develops cold induced
urticaria or angioedema with atypical responses to
CST, and although these patients should be followed
and treated in amanner similar to classic cases, amore
manageable disease would be expected.
Regarding atopy, a previous study suggested that
patients with ACU who also present atopic features
could have an increased severity of ACU symptoms.12
However, our results do not corroborate this finding,
and it seems that clinical features of the disease, such
as the age at symptom onset, the presence of atypical
ACU, or the symptoms severity are independent of the
presence of atopy.The recommended first-line therapy for the
management of patients with ACU is based on
avoiding triggering factors, along with the continuous
treatment with nonsedating H1-antihistamines
(evidence level A).2,4,5,13 However, reduction of
urticarial symptoms in many patients requires antihis-
tamines at high doses, up to 4 times the standard
dose.4,5,13-15 In our series, 85% of the patients who
were treated with antihistamines showed significant
clinical improvement. Rates of satisfactory clinical
response with antihistamines ranged from 60% to
70% in previous series.3,11,16 In contrast to cyclo-
sporine, omalizumab was found to be an effective
therapeutic alternative for patients with refractory
ACU.4,17,18 Importantly, the presence of other family
members with similar symptoms should always be
ruled out in patients with ACU, because specific
treatments (eg, antieinterleukin-1) have demon-
strated effectiveness in the management of familial
cold-induced urticaria syndromes.19-21 Moreover,
regardless of the prescribed treatment, self-limited
evolution can be seen in some patients with ACU. In
the present study, almost 26% of the patients experi-
enced complete symptom resolution (and therefore
no need for treatment) during the surveillance period,
with a mean disease duration until resolution of
5.1 years. In addition, there was a resolution rate
of 45% within the first 10 years. Rates of full
recovery of symptoms among similar studies vary
between 18% and 29%, with variable durations of
follow-up.9,12,16,22
In summary, although ACU represents a chronic
disease and patients can occasionally experience
life-threatening events, most subjects who receive
treatment can achieve a daily life without interfer-
ences. Different phenotypes of patients with ACU are
identified in routine clinical practice, and the
knowledge of their clinical characteristics would
improve their management. Some clinical features,
such as the age at disease onset and an accurate
severity assessment at baseline evaluation, may be
helpful to predict disease evolution, allowing clini-
cians to define a proper therapeutic strategy.
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Supplementary Fig 1. KaplaneMeier analysis showing
the proportion of cases with symptom resolution at the
different time points of disease evolution.
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Supplementary Fig 2. A, Critical temperature threshold (CTT) and (B) cold stimulation time
threshold (CsTT) values by categories of disease evolution (P = .03 and P = .54; respectively).
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